Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor
ObjectiveTo investigate the association between body mass index (BMI) and overall survival (OS) of patients with stage II/III gastric cancer (GC) after radical gastrectomy, and evaluate the potential influence of perioperative adjuvant chemotherapy (PAC).MethodsMedical records of 2,510 consecutive s...
Main Authors: | Wei Peng, Jing Dai, Chao-chan Liu, Dian Liu, Hua Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.899677/full |
Similar Items
-
Updated Adjuvant Chemotherapy for Gastric Cancer
by: Toshizo Takayama, et al.
Published: (2023-10-01) -
Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study
by: Pengfei Su, et al.
Published: (2023-10-01) -
Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
by: Xinxin Wang, et al.
Published: (2024-04-01) -
Comparison of the effects of perioperative and adjuvant chemotherapy on outcomes of operable gastric cancer: a retrospective cohort experience from a tertiary cancer center
by: Jamshed Ali, et al.
Published: (2023-03-01) -
Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial
by: Hironori Ishigami, et al.
Published: (2021-11-01)